(Q38194845)

30 August 2017

1 reference

title

Diagnosis and management of lymphomas and other cancers in HIV-infected patients (English)

1 reference

30 August 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614140%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Emanuela Vaccher

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614140%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Annunziata Gloghini

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614140%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Paolo De Paoli

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614140%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Silvia Franceschi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614140%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Liron Pantanowitz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614140%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Akin Abayomi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614140%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

language of work or name

English

0 references

publication date

11 March 2014

1 reference

Nature Reviews Clinical Oncology

30 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614140%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614140%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614140%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

223-238

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614140%20AND%20SRC:MED&resulttype=core&format=json

Global burden of cancers attributable to infections in 2008: a review and synthetic analysis

9 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Why do viruses cause cancer? Highlights of the first century of human tumour virology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Survival after AIDS diagnosis in Italy, 1999-2006: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

A retrospective analysis of AIDS-associated Kaposi's sarcoma in patients with undetectable HIV viral loads and CD4 counts greater than 300 cells/mm(3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Sarcomas other than Kaposi sarcoma occurring in immunodeficiency: interpretations from a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

21 January 2018

HIV-associated lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

HIV-associated lymphomas and gamma-herpesviruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

EBV-associated lymphomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Immunophenotypic and molecular analyses of acquired immune deficiency syndrome-related and Epstein-Barr virus-associated lymphomas: a comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Cancer burden in the HIV-infected population in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Pattern of cancer risk in persons with AIDS in Italy in the HAART era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Impact of 1993 revision of adult/adolescent AIDS surveillance case-definition for Europe. National Coordinators for AIDS Surveillance in 38 European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

The older HIV-positive adult: a critical review of the medical literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

The spectrum of human immunodeficiency virus-associated cancers in a South African black population: results from a case-control study, 1995-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Novel virally targeted therapies of EBV-associated tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Laboratory assays for Epstein-Barr virus-related disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

The Epstein Barr virus DNA levels as a tumor marker in EBV-associated cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Molecular and immunohistochemical detection of Kaposi sarcoma herpesvirus/human herpesvirus-8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

CpG methylation as a tool to characterize cell-free Kaposi sarcoma herpesvirus DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

p53 inhibition by the LANA protein of KSHV protects against cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

The Kaposi's sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Lymphomas occurring specifically in HIV-infected patients: from pathogenesis to pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Serum biomarkers of immune activation and subsequent risk of non-hodgkin B-cell lymphoma among HIV-infected women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Immune activation and inflammation in HIV-1 infection: causes and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Induction of IL-6 and IL-10 production by recombinant HIV-1 envelope glycoprotein 41 (gp41) in the THP-1 human monocytic cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

T-cell immunity to Kaposi sarcoma-associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

KSHV: pathways to tumorigenesis and persistent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Microvesicles and viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Modulation of B-cell exosome proteins by gamma herpesvirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

NF-kappaB signaling modulation by EBV and KSHV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Pathology of lymphoma in HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Lymphoid proliferations associated with human immunodeficiency virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Heterogeneous Epstein-Barr virus latent gene expression in AIDS-associated lymphomas and in type I Burkitt's lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Why would the incidence of HIV-associated Hodgkin lymphoma increase in the setting of improved immunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

The rising challenge of non-AIDS-defining cancers in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Immune reconstitution inflammatory syndrome: incidence and implications for mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Persistent immune activation in chronic HIV infection: do any interventions work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Effect of immune reconstitution on the incidence of HIV-related Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

The ultrastructural features of plasmablastic lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Plasmablastic lymphomas with MYC/IgH rearrangement: report of three cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

HHV-8+, EBV+ multicentric plasmablastic microlymphoma in an HIV+ Man: the spectrum of HHV-8+ lymphoproliferative disorders expands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Human herpesvirus 8-associated solid lymphomas that occur in AIDS patients take anaplastic large cell morphology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Extracavitary KSHV-associated large B-Cell lymphoma: a distinct entity or a subtype of primary effusion lymphoma? Study of 9 cases and review of an additional 43 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Extracavitary KSHV-positive solid lymphoma: a large B-cell lymphoma within the spectrum of primary effusion lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Early lesions in lymphoid neoplasia: Conclusions based on the Workshop of the XV. Meeting of the European Association of Hematopathology and the Society of Hematopathology, in Uppsala, Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Modern management of non-Hodgkin lymphoma in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Management of AIDS-related lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

How I treat HIV-associated lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Use of antineoplastic agents in patients with cancer who have HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Association of early HIV viremia with mortality after HIV-associated lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Impact of HAART on the clinical management of AIDS-related cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Stem cell transplantation for lymphoma patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Controversies in the treatment of Burkitt lymphoma in AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Prognostic factors in human herpesvirus 8-related lymphoproliferative disorders associated with HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Bortezomib-induced Epstein-Barr virus and Kaposi sarcoma herpesvirus lytic gene expression: oncolytic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Clinical aspects and management of Hodgkin's disease and other tumours in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Classical Hodgkin's lymphoma arising in different host's conditions: pathobiology parameters, therapeutic options, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Hodgkin lymphoma in patients with HIV infection: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

HIV infection and the risk of cancers with and without a known infectious cause

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

HIV infection, inflammation, immunosenescence, and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Hepatocellular carcinoma in HIV-infected patients: check early, treat hard

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Is Kaposi's sarcoma occurring at higher CD4 cell counts over the course of the HIV epidemic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

HIV infection, immunodeficiency, viral replication, and the risk of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Cancer screening in patients infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Human papillomavirus, human immunodeficiency virus and immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Cervical cancer prevention in HIV-infected women using the "see and treat" approach in Botswana

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Anal cancer prevention in HIV-positive men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Practising high-resolution anoscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Reduced lung-cancer mortality with low-dose computed tomographic screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Cutaneous malignancies among HIV-infected persons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Standardized Care Management Ensures Similar Survival Rates in HIV-Positive and HIV-Negative Patients With Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Cancer incidence in people with AIDS in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Cost-effectiveness of screening for anal precancers in HIV-positive men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Towards a better understanding of Kaposi sarcoma-associated immune reconstitution inflammatory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Assessment of immunovirological features in HIV related non-Hodgkin lymphoma patients and their impact on outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Uncommon hematologic malignancies. Case 1. Plasmablastic leukemia in HIV-associated multicentric Castleman's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Plasmablastic lymphoma: Cytologic findings in 5 cases with unusual presentation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Is plasmablastic lymphoma of the oral cavity an HHV-8-associated disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

HIV-associated human herpesvirus 8-positive primary lymphomatous effusions: radiologic findings in six patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Emerging antiretroviral drug interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Autologous stem-cell transplantation in patients with HIV-related lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Implications of the shifting pathobiology of AIDS-related lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

The immunological effects of concomitant highly active antiretroviral therapy and liposomal anthracycline treatment of HIV-1-associated Kaposi's sarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.31

Editorial comment: hemophagocytic syndrome--an HIV-associated quagmire

31 March 2020

1 reference

12 December 2020

Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection

1 reference

12 December 2020

Functions of the HIV-1 matrix protein p17.

1 reference

12 December 2020

Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency

1 reference

12 December 2020

Review of screening guidelines for non-AIDS-defining malignancies: evolving issues in the era of highly active antiretroviral therapy

1 reference

12 December 2020

Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011

1 reference

12 December 2020

Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome.

1 reference

12 December 2020

1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults

1 reference

12 December 2020

HIV-associated Hodgkin's lymphoma. Antiapoptotic pathways and mechanisms for immune escape by tumor cells in the setting of improved immunity

1 reference

12 December 2020

Differentiating HIV-associated non-Hodgkin's lymphomas with similar plasmacellular differentiation

1 reference

12 December 2020

10.1038/NRCLINONC.2014.31

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24614140%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference